Global Blood Therapeutics, Inc.
GBTDelisted Oct 5, 2022- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001629137
Global Blood Therapeutics, Inc. was delisted on Oct 5, 2022; its insiders filed their last Form 4 on Oct 6, 2022; 247 institutions reported holding it in 13F filings for Q3 2022, worth $4.67B in total; Soros Fund Management was the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:46 PM ET
Revenue flow, FY2021
Where the revenue went in FY2021, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2021: $303.1M (155.6% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 23, 2022 | Feb 24, 2021 | Feb 26, 2020 | Feb 27, 2019 | Feb 27, 2018 |
| Revenue | $194.7M | $123.8M | $2.11M | – | – |
| Cost of revenue | $3.32M | $1.99M | $48.0K | – | – |
| Operating expenses | – | – | – | $182.7M | $119.2M |
| Research and development | $212.1M | $155.1M | $174.6M | $131.3M | $87.8M |
| Selling, general and administrative | $267.0M | $210.9M | $117.1M | $51.4M | $31.4M |
| Operating income | -$287.7M | -$243.2M | -$281.3M | -$182.7M | -$119.2M |
| Interest expense | $104.1M | $48.9M | $31.2M | – | – |
| Income tax | $477.0K | $0 | $0 | – | $0 |
| Net income | -$303.1M | -$247.6M | -$266.8M | -$174.2M | -$117.0M |
| Margins and growth | |||||
| Operating margin | -147.7% | -196.4% | -13343.6% | – | – |
| Net margin | -155.6% | -200.0% | -12654.9% | – | – |
| Revenue growth, year over year | +57.3% | +5,773.0% | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 23, 2022 | Feb 24, 2021 | Feb 26, 2020 | Feb 27, 2019 | Feb 27, 2018 |
| Cash and equivalents | $684.7M | $494.8M | $302.2M | $275.4M | $198.3M |
| Short-term investments | – | $66.1M | $307.7M | $202.2M | $116.5M |
| Accounts receivable | $28.8M | $17.5M | $2.64M | – | – |
| Inventory | $58.2M | $40.2M | $1.28M | – | – |
| Total current assets | $802.0M | $632.2M | $628.0M | $485.8M | $324.3M |
| Property, plant and equipment | $34.9M | $37.9M | $27.1M | $15.0M | $16.6M |
| Total assets | $939.2M | $724.0M | $796.1M | $617.6M | $356.7M |
| Accounts payable | $15.1M | $19.1M | $10.6M | $6.05M | $7.18M |
| Total current liabilities | $88.0M | $79.0M | $71.5M | $33.8M | $26.3M |
| Long-term debt | $246.4M | $148.8M | $73.6M | – | – |
| Total liabilities | $742.8M | $307.8M | $217.4M | $44.8M | $37.9M |
| Shareholders' equity | $196.4M | $416.2M | $578.7M | $572.8M | $318.8M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 23, 2022 | Feb 24, 2021 | Feb 26, 2020 | Feb 27, 2019 | Feb 27, 2018 |
| Operating cash flow | -$256.8M | -$211.9M | -$194.4M | -$135.4M | – |
| Capital expenditures | $3.23M | $8.75M | $3.46M | $4.82M | $3.10M |
| Free cash flow | -$260.0M | -$220.6M | -$197.9M | -$140.2M | – |
| Depreciation and amortization | $5.91M | $8.32M | $8.61M | $4.61M | $1.66M |
| Stock-based compensation | $78.7M | $71.5M | $45.7M | $30.1M | $13.7M |
| Investing cash flow | $12.1M | $317.3M | -$76.9M | -$184.2M | – |
| Financing cash flow | $434.3M | $87.1M | $298.2M | $397.9M | – |
| Net change in cash | $190.0M | – | – | – | $106.3M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 40.4% | 57.7% | 2165.6% | – | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Aug 4, 2022 | 67.5M | +8.1% | SEC |
| Apr 29, 2022 | 65.1M | +4.5% | SEC |
| Feb 18, 2022 | 64.8M | +4.3% | SEC |
| Oct 29, 2021 | 64.4M | +4.3% | SEC |
| Jul 30, 2021 | 62.4M | +1.7% | SEC |
| Apr 30, 2021 | 62.3M | +2.2% | SEC |
| Feb 18, 2021 | 62.2M | +2.2% | SEC |
| Oct 30, 2020 | 61.8M | +2.6% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.